While the cause of psoriasis stems from your body's immune system, certain triggers can make symptoms ... It comes in several forms. Plaque psoriasis is the most common. Plaque psoriasis, the ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

One study found that pain was self-reported as a symptom in over 4 in 10 people with plaque psoriasis. For some others, the same immune system that causes plaque on your skin could instead inflame ...

Plaques may itch ... Certain conditions, such as infections, stress, and injuries, may trigger rash outbreaks. If you have psoriasis and notice a change in your usual rash pattern or location ...

Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

The chronic condition causes psoriasis plaques, which are raised, inflamed, and scaly patches of skin that can cause itchiness and pain. While the condition has never interfered with Goedert’s ...

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

Psoriasis, a chronic skin condition that causes inflammation in the form of raised plaques and scales on the body, affects more than 3% of the U.S. adult population. Symptoms often begin between ...

The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.